AmpleLogic Launches AI-Powered User Access Management Software to Close the Last Compliance Gap in Pharma IT

For most pharmaceutical and biotech companies, access management has quietly become the weakest link in an otherwise tightly controlled GxP environment. Manufacturing lines are validated. Lab instruments are qualified. Batch records are reviewed line by line. And yet, who actually has access to LIMS, eQMS, or eBMR and whether that access still makes sense often gets tracked in a spreadsheet that nobody updates until an inspector asks for it.

AmpleLogic is addressing that gap directly with the launch of its User Access Management (UAM) software, a purpose-built identity governance platform designed specifically for GxP-regulated organizations across pharma, biotech, medical devices, and R&D.

Read More:- https://www.amplelogic.com/products/user-access-management

Why This Matters Now?

Most identity and access management tools on the market were built for generic enterprise IT not for the realities of validated systems, training-linked qualifications, or FDA and MHRA inspection readiness. That mismatch shows up in predictable ways: orphaned accounts sitting active in LIMS months after an employee has left, lab analysts approving their own results because nobody flagged the conflict, or QA teams scrambling to pull together access logs the week before an audit.

AmpleLogic's UAM was built to solve these problems where they actually originate, inside the validated systems pharma companies run every day not as an afterthought bolted onto a generic IAM tool.

What's Inside the Platform?

The platform automates the entire identity lifecycle, from the moment HR triggers an onboarding event to the second an employee's access needs to disappear. A few capabilities stand out:

RPA-powered provisioning creates accounts across LIMS, eQMS, eBMR, DMS, and other validated systems automatically, cutting manual provisioning effort by roughly 80% according to early deployment data.

Training-linked role activation means a lab analyst or manufacturing operator can't access a GxP system until their LMS record confirms they're actually qualified to use it closing a compliance gap that audits flag again and again.

AI-driven segregation of duties analysis continuously checks for toxic role combinations, like a QA reviewer holding production access, and surfaces them before they become a finding rather than after.

Instant deprovisioning eliminates the lag between an employee's last day and the deactivation of their accounts, which is one of the more common sources of FDA 483 observations around access governance.

License intelligence tracks usage across tools like Empower, Chromeleon, and SAP in real time, with early customers reporting up to 40% reduction in license costs simply by reclaiming seats nobody was using.

Read more:- https://www.amplelogic.com/gamp-solutions/user-access-management

Built Around GxP, Not Adapted to It

What sets this apart from traditional IAM platforms isn't just the feature list it's the starting point. AmpleLogic UAM was designed around 21 CFR Part 11, EU Annex 11, and ALCOA+ data integrity principles from day one, rather than retrofitted with compliance add-ons after the fact. Every access change, login attempt, and permission grant generates an immutable, attributable audit trail that's ready for an FDA or MHRA inspector without any extra prep work.

The platform also connects natively into AmpleLogic's broader GAMP-validated suite, including LIMS, eQMS, DMS, LMS, and eBMR, along with HRMS, SAP, and Active Directory meaning access governance doesn't sit in a silo separate from the systems it's actually governing.

https://www.amplelogic.com/request-a-demo

Who It's For

The launch targets quality, IT, and compliance leaders across pharmaceutical manufacturing, biotech and biologics, medical devices, R&D laboratories, CROs, and CDMOs - organizations where the cost of a missed access review isn't just inefficiency, it's regulatory exposure.

"Access governance has been treated as an IT housekeeping task for too long in this industry," said a spokesperson familiar with the launch. "But in a GxP environment, who has access to what and whether that access is current is a data integrity issue, not just a security one. That's the problem we built this to solve."

Availability

AmpleLogic UAM is now available to new and existing customers across AmpleLogic's 30+ country footprint, with implementation support from the company's life sciences domain specialists, including IQ/OQ/PQ validation assistance for organizations bringing the platform into a validated environment.

Organizations interested in a demo or early access can connect with AmpleLogic directly to discuss deployment timelines and integration scope.

Contact us :- https://www.amplelogic.com/contact

Melange Tower, 2nd Floor, Wing-C, Patrika Nagar, HITEC City, Madhapur - 500081, Hyderabad, India
9:00 AM - 7:00 PM IST
Get in Touch:
Email Us: info@amplelogic.com
Call Us:
1800 2023 269 (Global)
+91-7396660171 (India)

Since 2010, AmpleLogic has been the trusted pharmaceutical software partner for 200,000+ users across 30+ countries - delivering a unified, AI-powered, 21 CFR Part 11 compliant platform that accelerates digital transformation across quality, laboratory, manufacturing, and regulatory operations in pharma, biotech, and life sciences.

This release was published on openPR.